Keyword
-
[06/09/2010 15:24] Fortis Healthcare eyes Singapore REIT-sources
NEW DELHI (Reuters) - Indian hospital operator Fortis Healthcare <FOHE.BO> is looking to list a real estate investment trust in Singapore in the next six months to house its property assets and is looking at a valuation of $600-700 million, a senior company executive said.
-
[06/09/2010 12:35] Solvay invests in hydrogen fluoride for China JV
BRUSSELS (Reuters) - Belgian drugs, chemicals and plastics maker Solvay <SOLB.BR> said on Sunday it had decided to build a new hydrogen fluoride installation for a Chinese joint venture.
-
[06/09/2010 12:30] Astra boosts emerging markets with Aurobindo deal
MUMBAI/LONDON (Reuters) - AstraZeneca <AZN.L> stepped up its drive into emerging markets on Monday by striking another licensing and supply deal with an Indian generic drugmaker, this time Aurobindo Pharma <ARBN.BO>.
-
[06/09/2010 12:00] Silence Therapeutics gets approach, shares jump
LONDON (Reuters) - Silence Therapeutics <SLN.L>, a British biotech company that has a research partnership with AstraZeneca <AZN.L>, said on Monday it had received an approach, sending its shares up 48 percent to a four-month high.
-
[06/09/2010 11:36] INTERVIEW - Foreign M&A of Japan generic drugmakers seen rising
TOKYO (Reuters) - Foreign drugmakers are likely to step up mergers and acquisitions in Japan's generic market as they seek distribution channels while the Japanese industry needs funds to make inroads in biotech products, a senior industry official said.
-
[06/09/2010 11:23] UK wants GSK's Avandia pulled as EU reviews safety
LONDON (Reuters) - GlaxoSmithKline's <GSK.L> diabetes drug Avandia should be pulled from sale because of concerns about heart risks, British drug regulators said on Monday ahead of a special European meeting on the drug's safety.
-
[06/09/2010 11:00] FOBT accuracy differs between men and women
NEW YORK (Reuters Health) - Both immunological and guaiac-based fecal occult blood tests (FOBTs) have a higher sensitivity and lower specificity for detection of advanced colorectal neoplasm among men than among women, German investigators report.
-
[06/09/2010 11:00] Serum HGF predicts NSCLC response to EGFR tyrosine kinase inhibitors
NEW YORK (Reuters Health) - Low pretreatment serum hepatocyte growth factor (HGF) levels predict a better response to EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC), researchers from Japan report in the August 2nd Clinical Cancer Research online.
-
[06/09/2010 11:00] Normal range serum phosphorus related to carotid IMT in young adults
NEW YORK (Reuters Health) - Increasing levels of serum phosphorus are independently related to carotid intima-media thickness (IMT), an indicator of subclinical atherosclerosis, in asymptomatic young adults.
-
[06/09/2010 11:00] Progestin helpful in endometrial hyperplasia
NEW YORK (Reuters Health) - Progestin therapy is beneficial in women with complex endometrial hyperplasia with and without atypia. Both endometrial cancer risk and the need for hysterectomy are significantly reduced, researchers report in the August issue of Obstetrics & Gynecology.
|
|